Fishman Vision

Fishman Vision is a clinical-stage biotechnology company dedicated to the development of novel treatments for ophthalmic conditions, with a primary focus on dry eye disease. The company's lead program, FV-001, is a proprietary topical formulation of caffeine that functions as an adenosine receptor antagonist to promote natural tear production. By targeting the lacrimal gland's signaling pathways, Fishman Vision aims to provide a more effective alternative to current anti-inflammatory treatments. The company was founded by Dr. Harvey Fishman, an experienced ophthalmologist and researcher. Fishman Vision continues to progress its clinical programs to address significant unmet needs in the ocular health market.